Análise de metanálises e ensaios clínicos relativos à utilização de estatinas em doenças cardiovasculares

Hudson Lacerda da Silva; Naira Villas Boas de Oliveira; Orenzio Soler

doi:10.5123/S2176-62232016000400013

Authors

Hudson Lacerda da Silva Hospital Universitário de Juiz de Fora, Juiz de Fora, Minas Gerais, Brasil
Naira Villas Boas de Oliveira 2Faculdade de Farmácia, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brasil
Orenzio Soler Faculdade de Farmácia, Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Pará, Brasil

DOI:

https://doi.org/10.5123/S2176-62232016000400013

Keywords:

HMG-CoA Reductase Inhibitors, Cardiovascular Diseases, Pharmaceutical

Abstract

ABSTRACT

OBJECTIVE:

To seek evidences for the use of statins in cardiovascular diseases and their economic costs in the context Unified Health System (Sistema Único de Saúde).

METHODS:

This is an exploratory, a bibliographic and qualitative research performed by data collection method from the systematic review.

RESULTS:

It was observed that the treatment with statins have been considered cost-effective in preventing cardiovascular diseases for high-risk users, when there is reduction of outcomes at low cost, especially in secondary prevention.

CONCLUSION:

It is necessary to review the clinical guidelines about the application of the cost-effectiveness concept and the funding of basic and specialized component of statins (high cost) for the use of simvastatin and atorvastatin and their relationship with the primary and secondary prevention of cardiovascular diseases.